KMT2A and acute myeloid leukemia: We confirmed the independent adverse prognostic significance of previously defined high-risk KMT2A translocation partners (ie, 4q21, 6q27, 10p11.2, 10p12, and 19p13.3).9,10 Therefore, our study serves as a consensus statement on fusion partner-based risk classification of childhood KMT2A-r AML, which will enable intergroup clinical trials and facilitate the performance of retrospective collaborative studies.